Summary:
In patients with clinically significant macular edema (CSME) in type 2 diabetes mellitus, low-dose atorvastatin (10-20 mg) as an adjunct to anti-VEGF therapy significantly improved functional anatomical outcomes compared to high-dose atorvastatin, though it was associated with minimal reported side effects.
| PICO | Description |
|---|---|
| Population | Patients with clinically significant macular edema (CSME) in the context of type 2 diabetes mellitus. |
| Intervention | Low-dose atorvastatin (10-20 mg) used as an adjunct to anti-vascular endothelial growth factor (anti-VEGF) therapy. |
| Comparison | High-dose atorvastatin, also administered as an adjunct to anti-VEGF therapy. |
| Outcome | Low-dose atorvastatin resulted in better functional (improved vision outcomes) and anatomical outcomes (reduction in macular thickness) compared to high-dose atorvastatin. Few or no significant side effects were reported for low-dose statin use. |
Source: Markan, Ashish, et al. “Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus.” Read article here.
